Granules India gets USFDA nod for generic Glycopyrrolate oral solution
Granules India announced that its subsidiary, Granules Pharmaceuticals Inc, has received approval from the US FDA for a generic version of Glycopyrrolate Oral Solution, 1 mg/5 mL. This anticholinergic medication is indicated for pediatric patients aged 3 to 16 years with neurological conditions associated with drooling.
Drugmaker Granules India on Tuesday said its arm Granules Pharmaceuticals Inc. has received approval from the US health regulator for a generic Glycopyrrolate oral solution indicated for pediatric patients having neurological conditions associated with drooling.
The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Glycopyrrolate Oral Solution of strength 1mg/5mL, Granules India said in a statement. It is bioequivalent and therapeutically equivalent to the reference listed drug, Cuvposa Oral Solution, 1 mg/5 mL of Merz Pharmaceuticals, LLC, it added.
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients aged three to 16 years who have neurological conditions associated with drooling problems, it added.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.